Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

Mérédis Favreau; Karin Vanderkerken; Dirk Elewaut; Koen Venken; Eline Menu

doi:10.18632/oncotarget.7440

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

Mérédis Favreau, Karin Vanderkerken, Dirk Elewaut, Koen Venken and Eline Menu _

PDF | HTML | How to cite

Oncotarget. 2016; 7:23128-23140. https://doi.org/10.18632/oncotarget.7440

Metrics: PDF 2629 views | HTML 3512 views | ?

Abstract

Mérédis Favreau1,2, Karin Vanderkerken1, Dirk Elewaut2,*, Koen Venken2,* and Eline Menu1,*

1 Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium

2 Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Faculty of Medicine and Health Sciences, VIB Inflammation Research Center and Ghent University, Ghent, Belgium

* These authors have contributed equally in this work

Correspondence to:

Eline Menu, email:

Keywords: myeloma, NKT cells, tumor immunity

Received: October 05, 2015 Accepted: February 05, 2016 Published: February 17, 2016

Abstract

Natural killer T (NKT) cells constitute a unique subset of innate-like T lymphocytes which differ from conventional T cells by recognizing lipid antigens presented by the non-polymorphic major histocompatibility complex (MHC) I-like molecule CD1d. Despite being a relatively infrequent population of lymphocytes, NKT cells can respond rapidly upon activation with glycosphingolipids by production of cytokines which aim to polarize different axes of the immune system. Due to their dual effector capacities, NKT cells can play a vital role in cancer immunity, infection, inflammation and autoimmune diseases. It is believed that modulation of their activity towards immune activation can be a useful tool in anti-tumor immunotherapeutic strategies. Here we summarize the characteristics of NKT cells and discuss their involvement in immunosurveillance. Furthermore, an update is given about their role and the progress that has been made in the field of multiple myeloma (MM). Finally, some challenges are discussed that are currently hampering further progress.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7440

Publication Alerts

Post-Publication Promotion

Reviews:

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?

Abstract